40 results about "Humanin" patented technology

The invention discloses a fusion protein of a bispecific antibody targeting a T cell and Her2 in series connection with IL-15 and a receptor thereof and an application of the fusion protein. Belongs to the technical field of biology. The fusion protein disclosed by the invention can be combined with a recombinant human CD3 protein and a recombinant human Her2 protein, can be combined with NK92 and SK-BR-3 cell lines, can stimulate NK92 cell proliferation, and can respectively cause ADCC effects mediated by T and NK cells; the antibody has important economic and social significance.

A conditionally active bispecific antibody comprising: an IgG antibody or antibody fragment that binds to human EpCAM protein, the IgG antibody or antibody fragment comprising a light chain variable region having three complementarity-determining regions L1, L2, and L3, and a heavy chain variable region having three complementarity-determining regions H1, H2, and H3; and at least one scFv antibody fragment that binds to a T lymphocyte protein linked to the C-terminus of at least one light chain of the IgG antibody or antibody fragment.

Compositions and methods for the treatment of retinal degeneration are provided. In one aspect, provided herein is adeno-associated virus (AAV) vector comprising an AAV capsid having encapsidated therein a vector genome comprising AAV inverted terminal repeat (ITR) sequences, a human protein kinase B (AKT) coding sequence, and expression control sequences that direct expression of AKT in a host cell.

The present application provides a monoclonal antibody targeting human carcinoembryonic antigen CEACAM5 / 6, and a bispecific antibody capable of simultaneously targeting human carcinoembryonic antigen CEACAM5 / 6 and human CD47, a preparation method and applications. Specifically, it relates to an anti-human CD47 antibody and antigen-binding fragments thereof capable of simultaneously (1) specifically binding to human CD47 protein and blocking its binding to SIRPalpha, thereby thus blocking the inhibitory effect of CD47 on SIRPalpha-expressing macrophages; (2) specifically binding to human carcinoembryonic protein CEACAM5 / 6. The present application also relates to a preparation method and uses of the bispecific antibody.

The invention relates to the technical field of biological medicine, in particular to a specific antibody for detecting or targeting ALDOA-K13 succinylation modification and application of the specific antibody. The specific antibody for detecting or targeting ALDOA-K13 succinylation modification can be specifically combined with a succinylation modification site of 13th lysine of human ALDOA protein, and is not combined with ALDOA of an unmodified type or other modified types. The invention provides a specific antibody for detecting or targeting ALDOA-K13 succinylation modification for the first time, and fills the blank of existing detection tools. The antibody not only has high specificity and sensitivity, but also can be used for developing a novel tumor diagnosis and prognosis detection method.

Provided herein are bispecific and multispecific antibodies that target tumor antigens and 4-1BB, the Fc region of which has a retained or enhanced effector function; in particular, the multispecific antibodies have binding specificity for human ROR1 protein and human 4-1BB protein. Also provided herein are methods of treating cancer using the antibodies or fragments thereof.

The invention discloses a polypeptide targeting CD38, a ligand of the polypeptide, a coupling drug and application of the polypeptide, and the polypeptide targeting CD38 has an obvious binding signal with human CD38 protein, which shows that the polypeptide targeting CD38 has very high targeting property on CD38. A ligand or a coupling drug can be prepared from any sequence of the peptide targeting CD38, or a combination of a plurality of sequences, and an active drug is loaded or connected. The compound has a good killing result on cells such as MM.1 S, MOLP-8, HL-60, MV-4-11, Kasumi-1, K562 and KG-1, and has a relatively high growth inhibition rate on tumor cells such as a human multiple myeloma MOLP-8 cell strain and a human leukemia tumor cell HL-60 cell strain.

Herein is reported an anti-TREM2 / A [beta] protein antibody comprising a first binding site that binds to human TREM2 and a second binding site that binds to human A [beta] protein, the first binding site comprising: a heavy chain variable domain comprising HVR-H1 of SEQ ID NO: 305, HVR-H2 of SEQ ID NO: 306 and HVR-H3 of SEQ ID NO: 307, and a light chain variable domain comprising HVR-L1 of SEQ ID NO: 309, HVR-L2 of SEQ ID NO: 310 and HVR-L3 of SEQ ID NO: 311 (TREM 23295), or a heavy chain variable domain comprising HVR-L1 of SEQ ID NO: 309, HVR-L2 of SEQ ID NO: 310 and HVR-L3 of SEQ ID NO: 311 (TREM 23295); the present invention relates to a single-chain variable domain comprising an HVR-H1 of SEQ ID NO: 329, an HVR-H2 of SEQ ID NO: 330, and an HVR-H3 of SEQ ID NO: 331, and a light chain variable domain comprising an HVR-L1 of SEQ ID NO: 333, an HVR-L2 of SEQ ID NO: 334, and an HVR-L3 of SEQ ID NO: 335 (TREM 23306); and a second binding site comprising: a heavy chain variable domain comprising HVR-H1 of SEQ ID NO: 09, HVR-H2 of SEQ ID NO: 10 and HVR-H3 of SEQ ID NO: 11, and in a light chain variable domain, HVR-L1 of SEQ ID NO: 13, HVR-L2 of SEQ ID NO: 14 and HVR-L3 of SEQ ID NO: 15 (A [beta] 8675).

Provided is an antibody for the treatment or prevention of autoimmune diseases, comprising a heavy chain variable region represented by SEQ ID NO: 1 or SEQ ID NO: 24, and a light chain variable region represented by SEQ ID NO: 6, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 25.

The present disclosure provides antibodies or fragments thereof having binding specificity for human ROR1 protein. In various examples, the antibodies or fragments thereof comprise VH CDRs and VL CDRs, or variants thereof, as disclosed herein. The disclosure also provides methods of treating cancer using the antibodies or fragments thereof.

The application belongs to the technical field of biotechnology, and particularly relates to an anti-TL1A nanobody and application thereof. The amino acid sequences of the complementarity determining regions CDR1, CDR2 and CDR3 of the nanobody are respectively shown as SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO:1. The application uses a llama natural nanobody library and combines phage display technology to successfully screen a high-affinity nanobody targeting TL1A. The antibody can specifically recognize human TL1A protein and a TL1A overexpression cell line, and has high affinity, high specificity and good physicochemical stability. Based on the characteristic of targeting TL1A, the nanobody has important application value in the precise diagnosis and targeted treatment of TL1A high-expression related diseases such as inflammatory bowel disease, rheumatoid arthritis, asthma and fibrosis, and is particularly suitable for developing a high-sensitivity in-vitro diagnostic kit and a novel biological therapeutic drug.

The invention belongs to the technical field of biology, and relates to a fully human anti-BCMA monoclonal antibody, a tandem antibody and application thereof. The invention provides an elutriation method of a BCMA protein monoclonal antibody, preparation of an IgG antibody and optimization of a series antibody of the IgG antibody. The scFv monoclonal antibody is composed of a light chain variable region VL, a heavy chain variable region VH and a human Fc fragment. The base sequence of the scFv monoclonal antibody is as shown in SEQ ID No.9, and the amino acid sequence of the scFv monoclonal antibody is as shown in SEQ ID No.23. The anti-human BCMA IgG antibody can specifically recognize and bind to human BCMA protein, and the binding activity of the anti-human BCMA IgG antibody is remarkably improved after the anti-human BCMA IgG antibody is expressed in a series scFv antibody form. The tandem antibody has a wide application prospect in detection of human BCMA protein and treatment of related target diseases, and a new idea is provided for development of antibody diagnostic reagents and drugs.

The application discloses application of recombinant human USP13 protein in preparation of a drug for treating diabetic cardiomyopathy, and belongs to the technical field of biological medicines.The application first proves that the expression of USP13 in myocardial tissue and serum is significantly reduced under the condition of diabetic cardiomyopathy (DCM); the recombinant human USP13 protein can obviously reduce the level of myocardial cell active oxygen, reduce the expression of NLRP3 inflammasome and active Caspase3 protein in a DCM in-vitro model induced by high sugar / palmitic acid; in a DCM mouse model injected with the recombinant human USP13 protein through a tail vein, myocardial cell apoptosis is inhibited, and the expression of NLRP3 inflammasome and the synthesis of TNF-alpha in the heart of the animal are reduced.USP13 is a human protein, has no obvious toxic side effects, is high in safety, is small in immunological rejection in theory, provides a new effective drug for the clinical treatment of DCM, and has important clinical application value and industrialization prospect.

Disclosed in the present invention are an EGFR x HER3 bispecific antibody-drug conjugate, a preparation method therefor, and use thereof. The structure of the antibody-drug conjugate is A-(L1-L2-L3-T)n, wherein A refers to an antibody; L1 refers to a coupling linker; L2 refers to x PEG spacers; L3 refers to an enzymatically cleavable or cleavable linker, or a non-cleavable linker; and T refers to an active small molecule. The antibody-drug conjugate provided in the present invention can bind to an HER3 protein of a human EGFR protein, has cytotoxicity to cancer cells expressing EGFR and / or HER3, and exhibits better efficacy and safety in in vivo tumor treatment.

The present disclosure provides an antibody or an antigen-binding fragment thereof, which specifically binds to PVRIG, has high binding affinity to human PVRIG protein and cynomolgus PVRIG protein, and has strong activity in both reporter gene level and CD8 T cell activation. Compared with known SRF813 and COM701, the antibodies of the present application exhibit more optimal in vitro activity, and some of the antibodies combined with PD-1 antibodies have obvious anti-tumor effect, making them excellent candidate drug molecules for therapeutic and diagnostic use.

The present disclosure provides a modified human OTC protein having improved properties for the treatment of OTC deficiency in a patient. Preferably, the protein of the disclosure is produced from a codon optimized mRNA suitable for administration to a patient suffering from OTC deficiency wherein upon administration of the mRNA to the patient, the protein of the disclosure is expressed in the patient in therapeutically effective amounts to treat OTC deficiency. The present disclosure also provides codon optimized mRNA sequences encoding wild type human OTC comprising a 5′ UTR derived from a gene expressed by Arabidopsis thaliana for use in treating OTC deficiency in a patient.

Herein is reported an antibody that binds to human A-beta protein wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain, the heavy chain variable domain and the light chain variable domain comprising a CDR selected from the group consisting of: (1) a CDR of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) a CDR of SEQ ID NO: 85, 89, 87, 81, 82, and 83; or (3) a CDR of SEQ ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.

The disclosure provides agents and methods for preventing or treating diseases associated with one or more antigens. The agents of the invention comprise RNA encoding chimeric proteins comprising an antigenic region. The antigenic region comprises one or more disease-associated antigens, immunogenic variants of fragments thereof. According to the invention, the chimeric proteins, in addition to the antigenic region, comprise a transmembrane domain and cytoplasmatic region, one or both of which are derived from a MHC-I homolog non-native to an organism from which the antigen originates.

Provided herein are antibodies or fragments thereof having binding specificity for human CD24 protein. In various examples, the antibodies or fragments thereof include VH and VL CDRs, or variants thereof, as disclosed herein. Also provided herein are methods of using the antibodies or fragments thereof to treat cancer.

The invention belongs to the technical field of gene therapy, and particularly relates to a recombinant expression system for expressing human GLB1 protein, a protein expression cassette, a recombinant adeno-associated virus vector and application of the recombinant adeno-associated virus vector in prevention and treatment of GM1 ganglioside storage diseases. In order to solve the problem that in an existing GLB1 gene expression system, due to the fact that a transcriptional regulation element combination is not systematically optimized, the expression efficiency in a central nervous system is insufficient, the codon-optimized human GLB1 gene and various different promoter-intron combinations are subjected to systematic pairing and functional verification; it is found that a recombinant expression system formed by a CB7 promoter-chimeric intron 1-codon optimized human GLB1 gene (SEQ ID NO: 2) is packaged into a recombinant adeno-associated virus AAV9.CB7. HGLB1co.bGH, the effect of treating the GM1 ganglioside storage disease is most remarkable, and the GM1 ganglioside storage disease is expected to be efficiently and safely prevented and radically treated.

The present application relates to the technical field of biotechnology, in particular to anti-human MxA antibody or functional fragment thereof and application thereof. The present application provides a plurality of monoclonal antibodies with high affinity to human MxA protein through computer simulation technology, and verifies the affinity of each mutation and its related application, thereby providing a reference for the research in the field of immune detection of human MxA.

The invention belongs to the technical field of biological medicines, and particularly discloses a polypeptide for protecting lung vascular endothelial cells and relieving lung injury and application of the polypeptide. The polypeptide is Humanin-G (HNG), and the amino acid sequence of the polypeptide is MAPRGFSCLLLLTGEIDLPVKRRA. The polypeptide is targeted to mitochondria of pulmonary vascular endothelial cells, provides protection from energy supply and cell survival roots, and has profound significance in improving functions of the pulmonary vascular endothelial cells and reducing the death rate of sepsis-induced acute lung injury (ALI). Researches show that when the polypeptide is used in the acute injury stage, lung inflammation of a model animal can be relieved by 25%-50%, the lung injury HE score can be reduced by about 50%, pulmonary edema can be relieved by about 30%, mitochondrial functions can be recovered by about 70%, the ATP yield can be increased by 30%, and the effect is excellent. Therefore, the invention provides a brand new strategy for maintaining the mitochondrial homeostasis by using the polypeptide so as to relieve lung injury.

This invention belongs to the field of biomedical technology and relates to a monoclonal antibody targeting BTN3A1 and its uses. The monoclonal antibody B1B7G2E4 of this invention has high human BTN3A1 binding activity and binding affinity, specifically binding to the human BTN3A1 protein on the cell membrane surface. It also cross-reacts with cynomolgus monkey BTN3A1, has a novel sequence, and is a new anti-BTN3A1 monoclonal antibody. Monoclonal antibodies targeting BTN3A1 have broad application prospects and can be used to treat various types of tumors. Furthermore, this antibody can be used in combination with other immunotherapies to improve overall treatment efficacy.

The invention discloses a bispecific antibody fusion protein targeting double antigens and application of the bispecific antibody fusion protein. Relates to the technical field of biology. The bispecific antibody fusion protein constructed by the invention can be specifically combined with human IL-5 protein and human IgE protein. Animal experiments show that the fusion protein can significantly reduce the level of key inflammatory factors in an allergic rhinitis model mouse body, effectively relieve nasal symptoms such as sneezing and rhinorrhea, and show a good treatment effect. A novel candidate protein drug is provided for targeted therapy of allergic diseases, especially allergic rhinitis, and the protein has wide development and application prospects and important social value.

The invention discloses a fusion protein targeting an EGFR (epidermal growth factor receptor) positive cell antibody and connected in series with TNF (tumor necrosis factor) alpha and application of the fusion protein. Belongs to the technical field of biology. The fusion protein can be combined with a recombinant human EGFR protein, can be combined with NK92 and SK-BR-3 cell lines, can cause an ADCC effect, and can cause apoptosis of tumor cell lines such as A549 and MCF7; the fusion protein has important economic and social significance.

The invention relates to the field of biological detection, in particular to a monoclonal antibody combination for detecting human IL-10 protein and application. The antibody combination comprises 8E10 and 10D12, the amino acid sequence of a complementary determining region of a heavy chain variable region of the monoclonal antibody 8E10 corresponds to SEQ ID NO.1-SEQ ID NO.3, and the amino acid sequence of a light chain variable region of the monoclonal antibody 8E10 corresponds to SEQ ID NO.4-SEQ ID NO.6; the amino acid sequence of a heavy chain variable region CDR of the monoclonal antibody 10D12 corresponds to SEQ ID NO.7 to SEQ ID NO.9, and the amino acid sequence of a light chain variable region CDR of the monoclonal antibody 10D12 corresponds to SEQ ID NO.10 to SEQ ID NO.12. The antibody combination ensures the repeatability of raw material production, provides a reliable basis for preparing in-vitro diagnostic tools such as high-sensitivity and high-stability ELISA kits and the like, and has a wide application prospect.

Herein is reported an anti-TREM2 antibody that specifically binds to human TREM2, the antibody comprising: HVR-H1 of SEQ ID NO: 305 in the heavy chain variable domain, HVR-H2 of SEQ ID NO: 306 and HVR-H3 of SEQ ID NO: 307, and HVR-L1 of SEQ ID NO: 309 in the light chain variable domain, HVR-L2 of SEQ ID NO: 310 and HVR-L3 of SEQ ID NO: 311 (TREM 23295), or HVR-H1 of SEQ ID NO: 329 in the heavy chain variable domain, HVR-H2 of SEQ ID NO: 330 and HVR-L3 of SEQ ID NO: 331 in the light chain variable domain, HVR-L2 of SEQ ID NO: 334 and HVR-L3 of SEQ ID NO: 335 ( wherein pSyk is not induced in the absence or in the presence of human A [beta] protein.

The invention relates to a preparation method of an APP gene humanized mutation vector and a non-human animal model. The APP gene humanized mutation vector comprises an APP gene knockout vector and an APP gene homologous recombination vector, and the APP gene knockout vector comprises at least one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4; the APP gene homologous recombinant vector comprises a part of nucleotide sequence for coding non-human animal APP protein, and the non-human animal APP protein contains human APP protein pathogenic mutation sites which are specifically as shown in SEQ ID NO: 5. Humanized mutation is carried out on the non-human animal APP, the original nature of the in-vivo environment of the non-human animal is maintained to the maximum extent, expression and folding of the gene are facilitated, the situation that protein folding is abnormal and conflicts with existing protein of the non-human animal are caused due to direct insertion of the human APP gene is prevented, and the method is closer to the real pathological process; and a more real and reliable disease model in pathology can be obtained.

The invention relates to a humanized anti-human IL-9 protein monoclonal antibody and application thereof. The humanized monoclonal antibody with low immunogenicity and high affinity is obtained by modifying a mouse anti-human IL-9 antibody through an advanced antibody humanization technology. Experiments prove that the compound can be specifically combined with human IL-9 protein, block the interaction between IL-9 and a receptor thereof, and effectively inhibit activation of related signal channels. In an in-vitro cell experiment and an animal model, the antibody has a remarkable regulating effect on related cytokine release, cell proliferation, inflammatory response and the like of allergic diseases, autoimmune diseases, tumor immunity and the like, is expected to be developed into an innovative biological medicine for treating related diseases, and can also be used for diagnosis and fundamental research of related diseases.

The problem addressed is to provide a new host cell that can be infected by a wide variety of morbilliviruses.　Provided is a mutant SLAM protein or an active fragment thereof that contains a mutant V domain derived from a V domain of a human SLAM protein and has an ancestral amino acid residue and / or an ancestral amino acid deletion.